




8 April 2024

dorsaVi releases video AI for upper limb tracking

Key highlights

- dorsaVi has released its video AI upper limb module, ahead of schedule, following demand from a major US customer who requested the feature
- The AI algorithm provides rapid, contactless range of movement analysis of the upper limb using video and supports a number of use cases
- The new feature builds on dorsaVi's growing suite of non-intrusive, video AI human movement analysis tools, complementing the Company's existing FDA-approved sensor technologies
- Future developments aligned with AI-powered movement analysis aim to extend this capability to include rapid functional activities including baseball pitches and golf swings

Melbourne, Australia, 8 April 2024: dorsaVi (ASX: DVL) (**dorsaVi** or the **Company**), developer of FDA approved wearable sensors and leader in human movement analytics, is pleased to announce it has successfully released a video AI algorithm that accurately tracks range of movement of the upper limb as part of its ViMove+ platform. The AI algorithm can automatically and rapidly report range and speed metrics for upper limb movement analysis using video. The release builds upon the successful development of the facial tracking and blurring algorithms released in March 2024¹ and is part of the Company's growing suite of AI-powered video analysis tools intended to reinforce dorsaVi's global leadership position in movement analytics.



¹ See ASX release 18 March 2024

² See ASX release 24 October 2022

³ See ASX release 24 June 2022

A major US physiotherapy customer specifically requested the upper limb feature in dorsaVi's ViMove+ platform in order to assist a broader cohort of patients and athletes. The Company believes that integrating upper limb analytics into its existing foundation of lower limb and spinal metrics will help expand its customer base.

The ViMove+ upper limb module complements dorsaVi's core sensor technology currently used by leading groups including Medtronic² and QBE Insurance Group³. The first release of the upper limb module allows allied health practitioners to assess upper limb injuries with accurate range of movement measures that also support right-side vs left-side comparisons. In addition, the algorithm can calculate the speed and maximum range of movement. All data is automatically captured, analysed and fed into an instant report, providing the therapist with valuable clinical insights, rapidly.

As part of the Company's AI-focused product development plan, the upper limb module will be released to dorsaVi's US customers initially, with Australian and UK customers to follow. The Company is currently finalising testing of an advanced swing-based module with elite athletes in order to verify the algorithms work at the higher rates required. The rapid functional module will be used to analyse complex movements in sports such as golf, tennis and baseball and will synchronise data from the video AI algorithm with sensor data, enabling high fidelity measurements. The Company expects the addition of this module will further expand the market potential of dorsaVi's ViMove+ platform.

Josh Hayes, PT, DPT, OCS, CSCS, said:

"We've been using the dorsaVi technology for some years on our patients with lower limb injuries at our US PT clinics, assessing their quality of movement and using the objective data to assist our return to play decisions. We wanted the same type of objective data for the upper limb and this started the discussion with dorsaVi about a video based module, utilizing dorsaVi's AI skills and sensor based algorithms. We are excited to see this come to light in the initial range of movement product, and very excited to see the swing-based module due out later this year."

The release of this announcement was authorised by the dorsaVi disclosure committee.

– ENDS –

For further information about dorsaVi, please contact:

dorsaVi

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
ar@dorsavi.com

Investors

Jed Pedersen
Vesparum Capital
+61 3 8582 4800
dorsavi@vesparum.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com